TAG:
Esoteric testing
Esoteric testing allows the analysis of rare substances or molecules that are not performed in a routine clinical lab. Many large commercial lab companies outsource complex tests to reference and esoteric testing labs. However, as technology continues to expand laboratory testing, tests that are considered esoteric today may become routine in just a few years. This is often the result of work performed by dedicated research and development scientists.
These tests are ordered when a physician requires additional detailed information, outside routine lab testing, to complete a diagnosis, establish a prognosis or choose and monitor a therapeutic regimen. Esoteric testing generally requires sophisticated instruments and materials as well as specialized personnel to perform and analyze results. The tests are typically outsourced to independent, specialized clinical reference laboratories because it is not cost effective for hospitals and physician office laboratories to perform the tests in-house.
These tests are ordered less frequently than routine tests and are generally priced higher than the routine tests. Esoteric testing is typically related to the medical fields such as endocrinology, genetics, immunology, microbiology, molecular diagnostics, oncology, serology and toxicology. Molecular diagnostics is the fastest growing segment of esoteric clinical testing.
The American Chemical Society publishes the Directory of Rare Analyses (DORA) which catalogues rarely ordered clinical tests and provides details on the labs performing them.
The challenges for labs performing such tests include not only finding qualified medical technologists, but also paying them the higher salaries they command because of the scarcity of their skill sets. In addition, materials used in these tests can also be costly, particularly because they are not usually purchased in large enough quantities to qualify for economies of scale.
Labs that perform these tests have capabilities including:
• Allergy
• Complex anatomic pathology with board-certified pathologist
• Bone markers
• Genetic analysis
• HLA testing
• Functional assays of the immune system
• Toxicology
In the U.S., labs that perform these tests range from ARUP Laboratories, Mayo Medical Laboratories, Quest Diagnostics Incorporated, and Laboratory Corporation of America to a growing number of specialty esoteric testing laboratories that offer proprietary esoteric assays. Examples of such specialty testing lab companies include Myriad Genetics, Genomic Health, and Foundation Medicine.
October 16, 2006 “Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XIII No. 14 – October 16, 2006 Issue
American Esoteric Laboratories, Inc. today announced that it has signed an extended, five-year contract to provide reference and esoteric testing services to the 14-hospital Baptist Memorial Health Care Corporation (BMHCC) in Memphis, Tennessee. This relationship was…
Evolving Strategy Guides American Esoteric Labs
By Robert Michel | From the Volume XIII No. 14 – October 16, 2006 Issue
CEO SUMMARY: Back in April 2004, when American Esoteric Laboratories, Inc.(AEL)launched operations, its declared ambition was to become a national esoteric testing firm. However, given the positive experiences from its acquisition of Memphis Pathology Laboratories in September 2004, AEL h…
Increased Competition For Hospital Lab Referrals
By Robert Michel | From the Volume XIII No. 13 – September 25, 2006 Issue
CEO SUMMARY: It’s a buyer’s market for hospital send-out testing because the supply of such tests exceeds demand. To fill excess capacity in their labs, some reference/esoteric lab companies are willing to offer rock-bottom prices to new clients. This situation is also motivating nati…
Some Random Insights About LabCorp’s Thinking
By Robert Michel | From the Volume XIII No. 13 – September 25, 2006 Issue
CEO SUMMARY: Having scooped up a number of mid-sized laboratory companies in recent years, Laboratory Corporation of America is working to integrate these operations and continue to expand its market share. In a recent conversation with financial analyst Bill Bonnello of Wachovia Securiti…
Turning Up the Heat in California
By R. Lewis Dark | From the Volume XIII No. 8 – June 12, 2006 Issue
FOR THE PAST TWO DECADES, CALIFORNIA HAS BEEN A PACE SETTER in healthcare and the clinical laboratory industry. Events in recent weeks seem to indicate that California will continue to move ahead of other regions in developments that influence the clinical laboratory industry. First, there is the im…
Failure of AD Pathlabs: Structural Weakness?
By Robert Michel | From the Volume XIII No. 1 – January 16, 2006 Issue
CEO SUMMARY: AD PathLabs is the latest in a string of business disappointments. Over the past decade, a number of anatomic pathology companies have proven that they can grow rapidly—attracting substantial volumes of specimens. But these companies seem to hit a financial wall that leads …
AmeriPath Will Acquire Specialty Laboratories
By Robert Michel | From the Volume XII No. 14 – October 3, 2005 Issue
CEO SUMMARY: It’s a surprise to most lab industry observers. AmeriPath, a company built around 400 anatomic pathologists working mostly in community hospitals, is acquiring a national reference/esoteric testing company. However, this deal may be better understood by looking at the motiv…
LabCorp Buys Esoterix For $150 Million in Cash
By Robert Michel | From the Volume XII No. 6 – April 18, 2005 Issue
CEO SUMMARY: Laboratory Corporation of America continues to display an appetite to grow by acquisition. However, its purchase of Esoterix, Inc. creates unique management problems for LabCorp, because Esoterix is itself a product of a lab acquisition strategy. Over the past ten years, Esot…
Labs in United Kingdom Pressured to Change
By Robert Michel | From the Volume XII No. 5 – March 28, 2005 Issue
CEO SUMMARY: Across the United Kingdom, the physical lay-out, instrumentation, and operation of laboratories is very close to that of laboratories in the United States and Canada. The source of most differences is how the healthcare system in the United Kingdom funds clinical services and…
“Lowest-Priced” Chickens Came Home to Roost
By R. Lewis Dark | From the Volume XII No. 4 – March 7, 2005 Issue
IN READING THE INTELLIGENCE BRIEFINGS on reference/esoteric laboratories in this issue, I found it interesting that American Medical Laboratories (AML) is no longer an independent lab company serving this market segment and that, of the four remaining independent lab companies focuse…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized